CHD1L: a novel oncogene

[1]  Feng Xu,et al.  CHD1L: a novel oncogene , 2013, Molecular Cancer.

[2]  Y. Qu,et al.  CHD1L promotes tumor progression and predicts survival in colorectal carcinoma. , 2013, The Journal of surgical research.

[3]  Feng Tian,et al.  Expression of CHD1L in bladder cancer and its influence on prognosis and survival , 2013, Tumor Biology.

[4]  M. Höglund,et al.  Detailed Analysis of Focal Chromosome Arm 1q and 6p Amplifications in Urothelial Carcinoma Reveals Complex Genomic Events on 1q, and SOX4 as a Possible Auxiliary Target on 6p , 2013, PloS one.

[5]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[6]  C. Park,et al.  CHD1L Is a Marker for Poor Prognosis of Hepatocellular Carcinoma after Surgical Resection , 2013, Korean journal of pathology.

[7]  Wei Wu,et al.  Understanding the Role of Long Noncoding RNAs in the Cancer Genome , 2013 .

[8]  X. Guan,et al.  SPOCK1 is regulated by CHD1L and blocks apoptosis and promotes HCC cell invasiveness and metastasis in mice. , 2013, Gastroenterology.

[9]  M. Scott,et al.  The chromatin remodeling factor Chd1l is required in the preimplantation embryo , 2012, Biology Open.

[10]  R. Conaway,et al.  Activation of the SNF2 Family ATPase ALC1 by Poly(ADP-ribose) in a Stable ALC1·PARP1·Nucleosome Intermediate* , 2012, The Journal of Biological Chemistry.

[11]  D. Xie,et al.  CHD1L Protein is overexpressed in human ovarian carcinomas and is a novel predictive biomarker for patients survival , 2012, BMC Cancer.

[12]  David G. Knowles,et al.  The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expression , 2012, Genome research.

[13]  P. Winyard,et al.  CHD1L: a new candidate gene for congenital anomalies of the kidneys and urinary tract (CAKUT). , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  X. Guan,et al.  Translationally controlled tumor protein induces mitotic defects and chromosome missegregation in hepatocellular carcinoma development , 2012, Hepatology.

[15]  J. Burnett,et al.  Current progress of siRNA/shRNA therapeutics in clinical trials , 2011, Biotechnology journal.

[16]  Xiaobing Fu,et al.  The macro domain protein family: Structure, functions, and their potential therapeutic implications , 2011, Mutation Research/Reviews in Mutation Research.

[17]  N. Carter,et al.  Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development , 2011, Cell.

[18]  X. Guan,et al.  Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion , 2010, Gut.

[19]  D. Xie,et al.  CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients. , 2010, The Journal of clinical investigation.

[20]  A. Llombart‐Bosch,et al.  Frequent deletion of CDKN2A and recurrent coamplification of KIT, PDGFRA, and KDR in fibrosarcoma of bone—An array comparative genomic hybridization study , 2010, Genes, Chromosomes and Cancer.

[21]  S. West,et al.  Poly(ADP-ribose)–Dependent Regulation of DNA Repair by the Chromatin Remodeling Enzyme ALC1 , 2009, Science.

[22]  X. Guan,et al.  Transgenic CHD1L Expression in Mouse Induces Spontaneous Tumors , 2009, PloS one.

[23]  M. Washburn,et al.  Poly(ADP-ribosyl)ation directs recruitment and activation of an ATP-dependent chromatin remodeler , 2009, Proceedings of the National Academy of Sciences.

[24]  D. Xie,et al.  Chromodomain helicase/adenosine triphosphatase DNA binding protein 1–like (CHD1l) gene suppresses the nucleus‐to‐mitochondria translocation of nur77 to sustain hepatocellular carcinoma cell survival , 2009, Hepatology.

[25]  W. Freeman,et al.  Gene expression profiles in HPV-immortalized human cervical cells treated with the nicotine-derived carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. , 2009, Chemico-biological interactions.

[26]  Zhenguo Wu,et al.  Isolation and characterization of a novel oncogene, amplified in liver cancer 1, within a commonly amplified region at 1q21 in hepatocellular carcinoma , 2007, Hepatology.

[27]  M. Bycroft,et al.  The macro domain is an ADP‐ribose binding module , 2004, The EMBO journal.

[28]  S. Batalov,et al.  A gene atlas of the mouse and human protein-encoding transcriptomes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[29]  S. Law,et al.  Chromosomal aberrations in esophageal squamous cell carcinoma among Chinese: gain of 12p predicts poor prognosis after surgery. , 2004, Human pathology.

[30]  J. Trent,et al.  Analysis of genetic alterations in primary nasopharyngeal carcinoma by comparative genomic hybridization , 2001, Genes, chromosomes & cancer.

[31]  J M Trent,et al.  Recurrent chromosome alterations in hepatocellular carcinoma detected by comparative genomic hybridization , 2000, Genes, chromosomes & cancer.

[32]  Robert A. Weinberg,et al.  Creation of human tumour cells with defined genetic elements , 1999, Nature.

[33]  R. Simon,et al.  Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. , 1999, The Journal of pathology.

[34]  J Isola,et al.  Molecular cytogenetics of primary breast cancer by CGH , 1998, Genes, chromosomes & cancer.

[35]  R. Perry,et al.  DNA-binding and chromatin localization properties of CHD1 , 1995, Molecular and cellular biology.